Rabies virus inactivated antigen, B

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Imovax
Generic Name
Rabies virus inactivated antigen, B
DrugBank Accession Number
DB10062
Background

Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.1

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Rabies virus strain PM-1503-3M antigen (propiolactone inactivated)
  • Rabies virus vaccine wistar strain PM-1503-3M (human)

Pharmacology

Indication

Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies.1

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Imovax RabiesInjection2.5 [iU]/1mLIntramuscularSanofi Pasteur Inc.2019-10-25Not applicableUS flag
Imovax RabiesInjection2.5 [iU]/1mLIntramuscularSanofi Pasteur Inc.1980-06-092021-12-07US flag

Categories

ATC Codes
J06AA06 — Rabies serum
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
C4HQF74XMW
CAS number
Not Available

References

General References
  1. DailyMed: Imovax rabies vaccine [Link]
RxNav
830464

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDiarrhea / Fever / Influenza-like illness or flu-like symptoms / Upper Respiratory Disease1
4CompletedPreventionRabies Vaccine Adverse Reaction1
4CompletedTreatmentRabies1
4Unknown StatusDiagnosticPrimary Immunodeficiencies (PID)1
3CompletedPreventionRabies (Healthy Volunteers)2
3CompletedPreventionRabies / Rabies Virus1
3CompletedTreatmentRabies1
3RecruitingPreventionRabies (Healthy Volunteers)1
2CompletedPreventionDengue Dengue Fever Dengue Hemorrhagic Fever / Dengue Diseases / Dengue Fever / Dengue Virus1
2CompletedPreventionPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular2.5 [iU]/1mL
Injection9 IU/ml
Injection, powder, for solution2.5 iu/mL
Injection2.5 mcg/0.5ml
Powder2.5 mcg/0.5ml
Injection, powder, for suspensionIntramuscular
Injection, powder, for suspensionIntramuscular2.5 iu/0.5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on November 30, 2015 21:23 / Updated on June 12, 2020 16:52